Vascular endothelial growth factor/vascular permeability function. The inhibitory eCect of dexamethasone on VEGF gene expression by tumour cells was markedly factor (VEGF/VPF) is a mitogen and chemotactic factor for endothelial cells in vitro and an angiogenesis and reduced by hypoxia which suggests that the upregulation of VEGF driven by hypoxia overcomes the eCect of the vascular permeability factor in vivo. Due to its properties, VEGF is a candidate for both angiogenesis and vascular dexamethasone. Dexamethasone did not alter VEGFR-2 mRNA levels in human umbilical endothelial cells. In a permeability/oedema induction which typically occur in glioblastomas. In this study we test the hypothesis that subcutaneous glioma tumour model, we observed only a 15% decrease in VEGF mRNA expression in dexamethe antioedema eCect of dexamethasone is mediated by downregulation of VEGF or VEGF receptor expression.
thasone treated animals (n=12) compared with controls animals (P=0.24). We conclude that dexamethasone VEGF mRNA and protein levels of two rat glioma cells lines, C6 and GS-9L, were determined after incubation may decrease brain tumour-associated oedema by reduction of VEGF expression in tumour cells. However, with dexamethasone under normoxic and hypoxic conditions. In normoxic C6 and GS9L cells, we observedIntroduction ago, glucocorticoids have served as major therapeutic substances for peritumoural brain oedema [12] . For this A common feature of malignant brain tumours is their ability to disturb the blood-brain barrier (BBB) and to reason, a large amount of research has been directed toward the elucidation of the possible mechanism by increase capillary permeability which subsequently leads to vasogenic brain oedema. Vasogenic brain oedema which glucocorticoids mediate their antioedema eCects. It is generally accepted that the favourable eCects of contributes substantially to the increase in brain volume leading to elevated intracranial pressure. Since their steroids are primarily related to a reduction in the permeability of a disrupted BBB [22] . Possible mechanisms that have been proposed to account for such stabilization of membrane lysosomes, and improvement that dexamethasone, the most commonly used steroid for the treatment of tumour-associated oedema, mediates in peritumoural microcirculation [39] . Although many eCorts to clarify this issue have been undertaken, the its eCect by downregulating the expression of VEGF or VEGF receptors. mechanism of steroid action on tumour-associated oedema is still not well defined.
It is also uncertain by which mechanism brain [20] . Beside its mitogenic activity, was reduced to 1%. Cells were then incubated either overnight (hydrocortisone, oestradiol, progesterone) or VEGF possesses a unique and strong vascular permeability activity in the Miles-Assay, being about 1000 for various time points (dexamethasone) with the following concentrations of the test substances: 1 nmol/l, times more potent than histamine [30] . VEGF is therefore also denominated vascular permeability factor (VPF). 10 nmol/l, 100 nmol/l, 1 mmol/l, 5 mmol/l and 10 mmol/l dexamethasone (Merck, Darmstadt); 10 mmol/l hydroRoberts and Palade have provided direct evidence that VEGF induces morphological changes in endothelial cells cortisone; 10 mmol/l oestradiol and 10 mmol/l progesterone (Sigma, Deisenhofen). To inhibit dexamethasone which are consistent with an increase in vascular permeability, such as an increase in fenestrae and pinocytic eCects, the glucocorticoid specific antagonist RU 43044 (gift of Roussel UCLAF, Paris, France) was coincubated vesicles [28] .
Several reports suggest a correlation between VEGF with 10 mmol/l dexamethasone at an equimolar ratio. expression and oedema formation in a variety of brain tumours. In vivo, VEGF is upregulated in highly vascu- thasone 1 mmol/l overnight. Subsequently, cells were washed in phosphate buCer (PBS), fixed in methanol at Recent findings in the rat female reproductive system suggest that VEGF mRNA expression is hormonally −20°C for 4 min and incubated for 1 h with the primary antibody. After washing in PBS, cells were incubated regulated in steroid-producing and steroid-responsive cells [7, 31] .
with a goat-anti mouse Cy3 secondary antibody. Microphotographs were taken with a Zeiss Axiophot. Based on these data, we investigated the hypothesis A similar experiment was carried out with subcutanethrough a 0.22-mm filter (Millipore). The total cell count was determined in a Fuchs-Rosenthal chamber and cell ously transplanted C6 and GS9L gliomas. For this experiment, 107 glioma cells were injected subcutaneously viability was assessed by trypan blue staining. The conditioned medium was concentrated #10-fold using into Sprague-Dawley (for C6) or Fisher rats (for GS9L). Fourteen days later, animals were killed, the tumour centricon with a 10-kDa cut-oC (Amicon, Beverly, USA). Aliquots were separated on a 12.5% polyacrylamide-SDS was removed and snap-frozen. Acetone-fixed cryosections (10 mm) were stained as described above.
gel and transferred to a PVDF membrane. The membrane was incubated with a polyclonal rabbit anti-VEGF antibody [3] directed against the N-terminal 16 amino acids
Hypoxia assay
of the mouse VEGF164 protein. A biotinylated goat antirabbit antibody was used as a secondary antibody For the hypoxia experiments, C6 and GS9L cells were cultured in an anaerobic (oxygen content approximately (Dianova, Hamburg, Germany). After incubation with an streptavidin-biotinylated horseradish peroxidase com-0.2%) gas chamber (Becton Dickinson) as previously described [25] . Incubations were carried out overnight plex (DAKO, Hamburg, Germany) visualization was performed by a chemoluminescence technique (ECL, (16-24 h). After removal from the gas chamber, cells were immediately processed for RNA extraction, or for Amersham International, Amersham, UK) and documented on a Kodak X-omat AR film (Kodak Ltd, reporter gene assay (see below).
Liverpool, UK).
RNA extraction and northern blot analysis Transplantation of GS9L cells
From cultured C6 and GS9L cells, total RNA was extracted with the Qiagen RNA isolation kit (RNeasy For in vivo experiments, syngeneic female rats (Fischer F344), weighing between 180 g and 200 g were purTotal RNA kit, Qiagen, Hilden, Germany) according to the instructions of the manufacturer. From HUVEC and chased from Charles River, Germany. For subcutaneous transplantation, animals were briefly anaesthesized with tumour tissues, total RNA was extracted according to the guanidinium thiocyanate method [4] . Aliquots of ether. GS9L cells [106] suspended in 0.5 mL PBS were slowly injected into the right flanks. Animals were RNA (10-20 mg) were electrophoresed in a 1.5% agarose gel containing 15% formaldehyde and subsequently monitored daily for tumour growth. Fourteen days after tumour implantation, 2 mg dexamethasone or 0.9% transferred to a Duralon membrane (Stratagene, La Jolla, USA) in 20×SSC. Filters were cross-linked with u.v.
saline was administered three times a day by i.p. injection. light (0.4 J/cm2) and hybridized at 68°C in hybridization solution (QuickHyb, Stratagene, La Jolla, USA) or as Sixteen tumour-bearing rats were separated into two groups. Six rats each were treated with dexamethasone described [16, 29] with the following random primed 32P-labelled cDNA probes: a full length 450 base-pair for 48 h and 72 h, respectively. For control purposes, four animals were injected with 0.2 mL 0.9% saline i.p. cDNA encoding for mouse VEGF164 [3], a 1.4-kb fragment encoding part of the extracellular domain of the every 8 h. After 48 h and 72 h, two animals of the control group together with six animals of the treatment KDR/VEGFR-2 gene [35] . For control of RNA loading we used a cDNA fragment coding for chicken b-actin.
group were killed 4 h after the last injection. Tumours were removed, measured, weighted and divided into two The mRNA levels were quantified by densitometric analysis using Image Master System DTS (Pharmacia, parts. One part was frozen in liquid nitrogen for RNA analysis, whereas the other part was fixed in 4% paraforBiotech). The expression indices of VEGF mRNAs were normalized against the b-actin value of each sample. maldehyde, embedded in paraBn wax and processed for histological analysis.
Conditioned media and Western analysis
After an incubation time of 16 h, the C6 or GS9L conditioned medium was removed, centrifuged for 10 min at 3000 r.p.m. to remove cells and filtered acetone-fixed frozen sections of transplanted C6 and
Results
GS9L gliomas also showed predominantly cytoplasmic staining in tumours of untreated animals (not shown),
Dexamethasone but not progesterone or oestradiol
and thus confirmed the in vitro results. These obser-
downregulates VEGF expression in normoxic C6
vations are consistent with the hypothesis, that C6 and and GS9L cells in vitro GS9L glioma cells express a functional glucocorticoid receptor. Consistent with the observed glucocorticoidWe observed a dexamethasone-concentration-dependent downregulation of VEGF protein in the C6 cell conspecific eCect on VEGF expression, hydrocortisone but not progesterone or oestradiol inhibited VEGF expression ditioned medium. Whereas 1 nmol/l and 10 nmol/l dexamethasone had no significant eCect on VEGF in the in C6 glioma cells in vitro (Figure 2) . conditioned medium, 100 nmol/l and higher concentrations of dexamethasone led to a significant decrease Dexamethasone downregulates VEGF mRNA of both secreted isoforms VEGF120 and VEGF 164 expression in hypoxic C6 and GS9L cells to a lesser (Figure 1) . Similar results were obtained in GS9L and extent than in normoxic cells MS mouse sarcoma cell lines (data not shown). We next determined whether this eCect is specific for glucoTo determine the influence of dexamethasone on VEGF mRNA levels Northern blot analyses were carried out corticoids and whether the glucocorticoid receptor is involved. When the glucocorticoid specific antagonist using RNA prepared from C6 and GS9L cells cultured in the presence of 1 mmol/l dexamethasone. We observed RU 43044 was added to C6 cells cultured in the presence of 10 mmol/l dexamethasone in an equimolar ratio, the 60% downregulation of VEGF mRNA in C6 cells (P= 0.015, five independent experiments), and 50% downexpression of VEGF was similar to the level observed in the untreated control cells (Figure 2 ). This finding is regulation in GS9L cells (P=0.01, three independent experiments) compared with untreated controls. consistent with the hypothesis that the eCect of dexamethasone on VEGF expression is mediated by the glucocorWe next carried out a time course experiment by incubating C6 cells for 6 h, 12 h, 24 h, 48 h with ticoid receptor. Because of the consistent and reproducible eCect on VEGF expression seen with 1 mmol/l dexamethasone, and observed a significant downregulation of VEGF mRNA after 6 h, which per-1 mmol/l dexamethasone all subsequent in vitro experiments were carried out using this concentration.
sisted for the various time points investigated (Figure 3 ). An 8.2 fold (C6) and 7.3 fold (GS9L) upregulation of As assessed by immunohistochemistry, unstimulated C6 cells showed a predominantly cytoplasmic localization VEGF mRNA was observed after 16-24 h of hypoxia. This upregulation of VEGF mRNA with hypoxia was of the glucocorticoid receptor in vitro. After stimulation with 1 mmol/l dexamethasone, a strong nuclear attenuated by dexamethasone to 7.1 fold (C6) and 5.2 fold (GS9L), so that, under hypoxic conditions, an inhiimmunostaining was observed (data not shown). Immunofluorescence studies which were carried out on bition of VEGF mRNA by dexamethasone of 13% in C6 Figure 1 . Concentration-dependent downregulation of VEGF protein by dexamethasone. Immunoblot analysis of conditioned media from C6 cells which were incubated with (1 nmol/l-10 mmol/l) or without (0) dexamethasone under normoxic conditions. Whereas 1 nmol/l and 10 nmol/l dexamethasone had no significant eCect on VEGF in the conditioned medium, 100 nmol/l and higher concentrations led to a significant dowregulation of the secreted isoforms VEGF120 and VEGF164. 
umbilical vein endothelial cells (HUVEC) in vitro
Consistent with the in vitro observations, we found a and in GS9L tumours in vivo similar VEGF receptor-2 mRNA expression in dexamethasone-treated and in untreated control GS9L tumours. To determine whether dexamethasone exerts its eCect on tumour vasculature integrity by regulating the expression of VEGF receptor-2, which is highly upregulDiscussion ated in tumour capillaries [25] , we used HUVEC because these cells constitutively express VEGFR-2 [21] .
We tested the hypothesis that the antioedema eCect of dexamethasone is mediated by downregulation of VEGF Incubation of HUVEC with 1 or 10 mm dexamethasone for 16 h did not aCect the mRNA level of the signalor VEGF receptor expression. Using two glial rat tumour cell lines we observed a strong downregulation of VEGF transducing VEGF receptor-2 ( Figure 5 ). To examine an of a hypoxia-inducible transcription factor (HIF-1a) to the hypoxia-responsive element (HRE) in the VEGF promoter [11] . In contrast, VEGF mRNA stability is under control of hypoxia-regulated sequences in the 3∞UTR of the VEGF mRNA [23] . Transcriptional activation and mRNA stability contribute to the upregulation of VEGF expression at diCerent timepoints. Hypoxia leads to an early (e.g. after 3 h) transcriptional activation of the VEGF gene in C6 glioma cells with an two-to threefold increase in transcription rate. After 15 h of hypoxia, increase in VEGF message is partly due to increased transcription (two-to threefold) and partly due to increased mRNA stabilization (two-to threefold) [16, 23] . We therefore investigated whether dexamethasone inhibits VEGF expression under both normoxic and under hypoxic conditions in C6 and GS9L cells. In vitro, and 30% in GS9L cells). It is unclear why dexamethasone downregulates VEGF to a far greater extent in normoxic than in hypoxic glioma cells. The VEGF gene contains mRNA and protein expression was observed following incubation of cells with dexamethasone. This eCect several binding sites for the transcription factor AP1 [36] . The dexamethasone-glucocorticoid receptor comwas dependent upon concentration. A significant downregulation of VEGF protein expression was seen at conplex prevents the AP1 transactivator complex from stimulating transcription of genes containing an AP1 centrations of 100 nmol/l dexamethasone or higher. Since VEGF downregulation could also be achieved by binding site [18] . This has also been shown for the VEGF gene [10] . Possibly dexamethasone inhibits hydrocortisone, but not by progesterone or oestradiol, our results suggest a glucocorticoid receptor-specific AP1-dependent transcription in the VEGF gene, but leaves the activity of hypoxia-dependent transcription downregulation of VEGF in the glioma cell lines used. This is further supported by our observation that downrefactors, such as HIF-1a, unaltered. In addition, dexamethasone may interfere to some extent with the increase gulation of VEGF by dexamethasone was completely reversed by coincubation with the glucocorticoid specific in VEGF mRNA stability observed under hypoxic conditions. antagonist RU 43443. In line with these findings, we observed expression of the glucocorticoid receptor in C6
We also wanted to determine whether VEGF is downregulated by dexamethasone in gliomas in vivo. For these glioma cells in vitro and in vivo and nuclear translocation of the ligand-receptor complex after addition of dexaexperiments, GS9L cells were injected subcutaneously into syngeneic rats. Animals were treated with 6 mg methasone in vitro, suggesting that C6 cells possess a functional glucocorticoid receptor. These findings supdexamethasone per day for 48 and 72 hours, respectively. By Northern analysis, we observed no significant port the hypothesis that the dexamethasone eCect on VEGF expression is mediated by the glucocorticoid (e.g. 15%, P=0.24) downregulation of VEGF in dexamethasone-treated tumours compared with controls. receptor.
Hypoxia has been shown to be a major inducer of Although there are several possible explanations for the reduced potency of dexamethasone to inhibit VEGF VEGF expression in vitro [25, 32] . Ikeda et al. demonstrated that VEGF upregulation in glioma cells under expression in vivo, the most likely is that in vivo a considerable proportion of tumour cells suCer from hypoxia is due to both an increase in mRNA stability and transcriptional activation [16] . Transcriptional actihypoxia. The tumours we analysed well exceeded the diameter of 2 mm which, based on experimental models, vation of the VEGF gene is mainly achieved by binding 
